Sun Pharmaceutical Industries Limited (SUNPHARMA) ka pichle ek saal (May 2025 se May 2026 tak) ka structural trend chart taiyaar hai. India ki sabase badi pharmaceutical company aur Nifty Pharma index ka sabase bada heavyweight hone ke naate, iska price action US specialty generic pipeline, domestic chronic segment growth aur USFDA manufacturing plant compliance status ko closely follow karta hai.
​Sun Pharma Stock Key Highlights (May 2025 - May 2026)
​Specialty Portfolio Led Growth (2025): May 2025 ke dauran stock ne ₹1,480 ke paas ek solid consolidation baseline banayi thi. Global specialty product sales (jaise Ilumya, Cequa) ki behtar scaling aur strong domestic market share ke sahare institutional buyers ne isme lagatar heavy long delivery accumulation banaye rakha.
​Saal Ka Highest Peak: Double-digit EBITDA growth aur solid financial metrics ke dum par December 2025 ke mid mein stock ne apna saal ka sabase highest peak ₹1,880 par lagaya.

What's new in this chart? 📈

Moving Averages (MA): We have added 5-day and 10-day moving averages. You can see that due to the recent decline, Price is now trading below the moving average, which is a sign of weakness in the short-term. Daily Range: Gray shaded area in the chart shows the fluctuations between high and low of the day.

Regional Distribution

Agar hum duniya bhar ke gamers ki baat karein, toh Asia lagatar sabse aage bana hua hai:

Asia-Pacific: ~46-49% share. China, India, Japan, aur South Korea ki vajah se yeh sabse bada market hai.

North America: ~27% share.
Europe: ~18% share.

Pro Tip: India aur Southeast Asia jaise regions mein mobile-first gamers ki vajah se audience base sabse tezi se expand ho raha hai, jabki Western markets mein revenue per user (ARPU) zyada hai.

Good morning

GOLD SELL 4376
TP4370
TP4365
TP4360
TP4355
TP4350
SL4388

GOLD SELL
TP2HIT DONE 100+ PIPS

GOLD SELL
TP3HIT DONE 150+ PIPS